Abeona Therapeutics (ABEO) Stock: Buy, Sell, or Hold?
ABEO - Abeona Therapeutics Inc. Common Stock
$5.13
0.10 (1.99%)
▲
5d:
-3.02%
30d:
-13.49%
90d:
-21.68%
WAIT
LOW Confidence
Analysis Updated: Oct 2, 2026 12:00 AM ET
Earnings: Nov 11, 2026
Get Alerted When ABEO Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: ABEO shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: ABEO shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: ABEO is currently trading at $5.13, which is considered oversold relative to its 30-day fair value range of $5.25 to $5.88. From a valuation perspective, the stock is trading at a discount (Forward PE: -24.2) compared to its historical average (21.7). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, ABEO is showing sideways momentum. The price is currently testing key support at $4.99. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock scores a mixed 43/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $18.88 (+275.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, ABEO is showing sideways momentum. The price is currently testing key support at $4.99. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock scores a mixed 43/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $18.88 (+275.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$5.25 -
$5.88
Company Quality Score
49/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
84.3%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (43/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 275.2% below Wall St target ($18.88)
- BULLISH: Market expects only 0% annual growth - appears undervalued
- WARNING: Composite score 49/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$5.25 -
$5.88
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$4.99
Resistance Level
$5.90
Current Trend
Sideways
Technical data as of
Oct 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-24.24
Wall Street Target
$18.88
(+275.2%)
Revenue Growth (YoY)
2745.0%
Profit Margin
-246.4%
PE vs Historical
-24.2 vs 21.7
CHEAP
Share & Embed Analysis
Last updated: October 05, 2026 1:31 PM ET
Data refreshes hourly during market hours. Next update: 2:31 PM
Data refreshes hourly during market hours. Next update: 2:31 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ABEO showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
RVMD
Revolution Medicines Inc |
STRONG BUY
23 analysts |
$257 | 48 HOLD |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$74 | 62 BUY |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
20 analysts |
$95 | 54 HOLD |
|
JANX
Janux Therapeutics Inc |
STRONG BUY
18 analysts |
$36 | 64 BUY |
|
BEAM
Beam Therapeutics Inc |
STRONG BUY
15 analysts |
$52 | 68 BUY |
